Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for ...

CNW/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the ...

LFTs are a panel of blood tests that help detect liver injury, cholestasis or synthetic dysfunction. Learn what each marker ...

Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi (seladelpar) for adults with primary biliary ...

With lifestyle disorders and non-communicable diseases on the rise, many people routinely undergo Liver Function Tests (LFTs) ...

Liver Awareness Month, observed each October, increases public understanding of the causes, symptoms, and outcomes of liver disease and highlights steps that can be taken at both the individual and ...

Detailed price information for Mirum Pharmaceuticals Inc (MIRM-Q) from The Globe and Mail including charting and trades.

Last night, Opportunity Finance Network (OFN), the nation's leading network and intermediary focused on community development ...

Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Martin Mackay, Ph.D., has joined its Board of Directors. Mackay is a globally ...

Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...

Pharmaceutical leader Gilead Sciences is witnessing significant returns from its strategic $4.3 billion acquisition of Cymabay Therapeutics. The centerpiece of this transaction, the medication ...

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ...